Literature DB >> 7832599

Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly.

D C McCrory1, D B Matchar, G Samsa, L L Sanders, E L Pritchett.   

Abstract

BACKGROUND: Our goal was to determine whether patient age affects a physician's reported likelihood of using anticoagulant therapy or the intensity of anticoagulant therapy for patients with nonvalvular atrial fibrillation.
METHODS: We surveyed a nationwide sample of 1189 randomly selected office-based practitioners in three strata: primary care (geriatrics, internal medicine, family practice, and general practice), cardiology, and neurology. A vignette-based questionnaire was used to measure attitudes and beliefs regarding anticoagulation risks and effectiveness, barriers to anticoagulation in clinical practice, and likelihood of using anticoagulation and target intensity of anticoagulation at three patient ages (55, 65, and 75 years) for four clinical scenarios (chronic non-valvular atrial fibrillation with mild left atrial enlargement, intermittent or paroxysmal atrial fibrillation, recent-onset atrial fibrillation, and atrial fibrillation with recent [3 months] embolic stroke).
RESULTS: The overall response rate was 38%. The mean likelihoods of using anticoagulation for the three ages were unequal (P < .0001) for each scenario. Most physicians were "very" or "somewhat" likely to use anticoagulant therapy for a 65-year-old with left atrial enlargement (71%), intermittent or paryoxysmal atrial fibrillation (68%), recent-onset atrial fibrillation (86%), or embolic stroke (96%). Fewer physicians were likely to use anticoagulant therapy for a 75-year-old with left atrial enlargement (63%), intermittent or paroxysmal atrial fibrillation (56%), recent-onset atrial fibrillation (80%), or embolic stroke (93%). Among physicians equally likely to use anticoagulation for 65- and 75-year-old patients, intensity of anticoagulant therapy (target international normalized ratio or prothrombin time ratio) was lower (P < .04) for the 75-year-old.
CONCLUSION: Anticoagulant therapy may be less often and less intensively used for elderly patients with nonvalvular atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7832599

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  47 in total

Review 1.  Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use.

Authors:  D McCormick; J H Gurwitz; R J Goldberg; J Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-01       Impact factor: 2.300

3.  Racial differences in the utilization of oral anticoagulant therapy in heart failure: a study of elderly hospitalized patients.

Authors:  S A Ibrahim; C K Kwoh; D L Harper; D W Baker
Journal:  J Gen Intern Med       Date:  2000-02       Impact factor: 5.128

4.  Managing atrial fibrillation in elderly people.

Authors:  K M English; K S Channer
Journal:  BMJ       Date:  1999-04-24

Review 5.  Challenges of prescribing low-dose drug therapy for older people.

Authors:  P A Rochon; J P Clark; J H Gurwitz
Journal:  CMAJ       Date:  1999-04-06       Impact factor: 8.262

6.  Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; R G Hart; G Feldman; J L Blackshear; D C Anderson
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

7.  Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation.

Authors:  T J Bungard; W A Ghali; F A McAlister; A M Buchan; A J Cave; P G Hamilton; L B Mitchell; A Shuaib; K K Teo; R T Tsuyuki
Journal:  CMAJ       Date:  2001-08-07       Impact factor: 8.262

Review 8.  Guidelines for stroke prevention in patients with atrial fibrillation.

Authors:  P A Howard
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 9.  Why is warfarin underutilized in patients with atrial fibrillation?

Authors:  Greg C Flaker; John Schutz
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

10.  Warfarin for non-valvar atrial fibrillation: still underused in the 21st century?

Authors:  S Bo; G Ciccone; L Scaglione; C Taliano; M Piobbici; F Merletti; G Pagano
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.